G01N 2333/70521
Cd28, cd152
G01N2333/70521 (Cd28, cd152) appears on 43 US grants and 117 published applications in this corpus.
Search patents in G01N- Granted patents
- 43
- Published applications
- 117
- Assignees
- 88
- Inventors
- 333
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 1 | 3 |
| 2010 | 1 | 0 |
| 2011 | 1 | 2 |
| 2012 | 2 | 1 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 3 |
| 2016 | 0 | 3 |
| 2017 | 1 | 2 |
| 2018 | 2 | 15 |
| 2019 | 4 | 6 |
| 2020 | 6 | 10 |
| 2021 | 1 | 11 |
| 2022 | 4 | 10 |
| 2023 | 4 | 8 |
| 2024 | 2 | 7 |
| 2025 | 6 | 15 |
| 2026 | 4 | 14 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Multi-domain CD1a antagonist/PD-1 agonist antibody molecules15 Sep 2026US 12,735,491 B2Immunocore Limited
- Bispecific antibody targeting TIM3 and use thereof23 Jun 2026US 12,662,534 B2L&L Bio Co., Ltd., Ningbo, China
- Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof9 Jun 2026US 12,649,793 B2BioAtla, Inc.
- Biomarkers for determining the efficacy of immune checkpoint inhibitors10 Mar 2026US 12,571,799 B2National Cancer Center
- Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof25 Nov 2025US 12,479,919 B2Akeso Pharmaceuticals, Inc.
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof17 Sep 2026US 2026/0274952 A1Akeso Pharmaceuticals, Inc.
- ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof27 Aug 2026US 2026/0250390 A1BioAtla, Inc.
- Biosignature integration to assess therapy response in breast cancer13 Aug 2026US 2026/0235605 A1Prelude Corporation
- Compositions and Methods for Modulation of Immune Responses6 Aug 2026US 2026/0227408 A1Flagship Pioneering Innovations VI, LLC
Most cited
By later US patents
- Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease39US 7,465,446 B2Medarex, Inc. · 2008
- Muteins of tear lipocalin and methods for obtaining the same12US 8,313,924 B2Pieris AG · 2012
- Muteins of tear lipocalin and methods for obtaining the same11US 10,046,027 B2Pieris Pharmaceuticals GmbH · 2018
- Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease11US 7,744,875 B2Medarex, Inc. · 2010
- Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist6US 7,494,779 B22009